-
Home
- About PMI
-
Smoke-free approach
- What is harm reduction?
- Absence of combustion
- Nicotine
- The role of smoke-free products
- Tar
- Tobacco Regulation
Smoke-free approachOffering smoke-free alternatives to adult smokers is a sensible, complementary addition to existing tobacco control strategies.Read More -
Research
- Our Scientific Approach
- Our Findings
- PMI Publications Library
- Literature Reviews
- Independent Studies
- Investigator Initiated Studies (IIS)
- Latest PMI Science Booklet
- Facts and figures on our smoke-free future
ResearchPMI is committed to sharing results as the development and scientific assessment of smoke-free products advance.Read More -
Our Products
- Tobacco Heating System
- Oven Heating System
- MESH Vaping System
- Disposable Vaping System
- Oral Nicotine Pouches
- Nicotine salts product
Our ProductsPMI believes that offering a range of smoke-free alternatives is essential to ensure individual smokers are able to find a smoke-free product that they can fully switch to.Read More -
News & Events
- Scientific Update Magazine
- Open Science Events
- News
- Conferences Calendar
- Media Library
News & EventsRead our most recent articles and catch up on our latest events and conference presentations.Read More - Contact Us
GladiaTOX: GLobal Assessment of Dose-IndicAtor in TOXicology
Summary: GladiaTOX R package is an open-source, flexible solution to high-content screening data processing and reporting in biomedical research. GladiaTOX takes advantage of the'tcpl' core functionalities and provides a number of extensions: it provides a web-service solution to fetch raw data; it computes severity scores and exports ToxPi formatted files; furthermore it contains a suite of functionalities to generate PDF reports for quality control and data processing. Availability and implementation: GladiaTOX R package (bioconductor). Also available via: git clone https://github.com/philipmorrisintl/GladiaTOX.git.
Plasma protein binding and tissue retention kinetics influence the rate and extent of nicotine delivery to the brain
Results and lessons learned from the sbv IMPROVER metagenomics diagnostics for inflammatory bowel disease challenge
Tobacco Alkaloid Assessment in a DSS-Induced Colitis Mouse Model with a Fully Humanized Immune System
Dissection of Cancer Mutational Signatures with Individual Components of Cigarette Smoking
Shotgun lipidomics of rodent tissues
Systems biology reveals anatabine to be an NRF2 activator
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. Our RRPs are smoke-free products that produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.